statistiche ricercatore

Continente	#
EU - Europa	955
NA - Nord America	873
AS - Asia	403
SA - Sud America	67
AF - Africa	19
OC - Oceania	3
Continente sconosciuto - Info sul continente non disponibili	1
Totale	2.321

Nazione	#
US - Stati Uniti d'America	852
DE - Germania	308
PL - Polonia	298
CN - Cina	138
SG - Singapore	111
UA - Ucraina	82
GB - Regno Unito	78
RU - Federazione Russa	71
BR - Brasile	60
HK - Hong Kong	49
FI - Finlandia	34
IT - Italia	29
VN - Vietnam	25
TR - Turchia	20
IE - Irlanda	13
CA - Canada	12
CZ - Repubblica Ceca	12
IN - India	12
FR - Francia	10
IR - Iran	9
KR - Corea	6
MX - Messico	6
ZA - Sudafrica	6
ET - Etiopia	5
SE - Svezia	5
MU - Mauritius	4
TH - Thailandia	4
BD - Bangladesh	3
EG - Egitto	3
GE - Georgia	3
ID - Indonesia	3
JP - Giappone	3
PH - Filippine	3
PK - Pakistan	3
AU - Australia	2
AZ - Azerbaigian	2
BG - Bulgaria	2
CL - Cile	2
ES - Italia	2
IL - Israele	2
NL - Olanda	2
PE - Perù	2
SK - Slovacchia (Repubblica Slovacca)	2
AL - Albania	1
AR - Argentina	1
AT - Austria	1
BA - Bosnia-Erzegovina	1
BZ - Belize	1
DK - Danimarca	1
DO - Repubblica Dominicana	1
EC - Ecuador	1
EU - Europa	1
HR - Croazia	1
JM - Giamaica	1
JO - Giordania	1
KE - Kenya	1
KZ - Kazakistan	1
LK - Sri Lanka	1
LT - Lituania	1
LV - Lettonia	1
MY - Malesia	1
NP - Nepal	1
NZ - Nuova Zelanda	1
OM - Oman	1
PY - Paraguay	1
TJ - Tagikistan	1
Totale	2.321

Nome	#
Long Pentraxin-3 inhibits FGF-dependent angiogenesis andgrowth of steroid hormone-regulated tumors	303
alphavbeta3 Integrin-dependent antiangiogenic activity of resveratrol stereoisomers.	281
The pattern recognition receptor PTX3 as an angiostatic epithelial/stromal FGF-targeting inhibitor in hormonal cancers	230
Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.	208
ANTI-ANGIOGENIC ACTIVITY OF A NEUTRALIZING HUMAN SINGLE-CHAIN ANTIBODY FRAGMENT AGAINST FIBROBLAST GROWTH FACTOR RECEPTOR 1	195
Long Pentraxin-3 As An Epithelial-Stromal Fibroblast Growth Factor-Targeting Inhibitor In Prostate Cancer.	191
Fibroblast growth factor-2 antagonist and Antiangiogenic activity of long-pentraxin 3-derived synthetic peptides	186
Long pentraxin-3 inhibits epithelial-mesenchymal transition in melanoma cells.	181
Delivering cytokines at tumor site: The immunocytokine-conjugated anti-EDB-fibronectin antibody case	163
Beta-Galactosylceramidase deficiency: neurovascular implications	154
Inhibition of angiogenesis by β-galactosylceramidase deficiency in globoid cell leukodystrophy	138
Gremlin as a novel pro-angiogenic VEGFR2 agonist: production of a biologically active recombinant form in S2 Drosophila cells	128
Totale	2.358

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	146	0	0	0	0	0	24	11	24	30	17	25	15
2021/2022	119	5	28	2	0	2	4	6	7	4	20	11	30
2022/2023	95	15	7	8	5	10	22	0	11	7	1	5	4
2023/2024	156	6	3	21	7	7	17	11	7	27	8	6	36
2024/2025	284	3	4	4	38	24	30	32	20	33	16	48	32
2025/2026	342	47	64	57	79	91	4	0	0	0	0	0	0
Totale													2.358